Insmed Announces Additional Information In Compliance With NASDAQ Rules



    RICHMOND, VA., March 16 /CNW/ - Pursuant to NASDAQ Marketplace Rule
4350(b) (the "NASDAQ Rule") any Company, whose securities are listed on one of
the NASDAQ stock exchanges, that receives a going concern audit opinion in one
of its filings with the Securities and Exchange Commission is required to
disseminate this information to the public. In compliance with this NASDAQ
Rule, Insmed Incorporated, today announced that it has received a going
concern audit opinion for its financial statements dated as of December 31,
2006, and filed as part of its Annual Report on Form 10-K with the Securities
and Exchange Commission. This going concern audit opinion was given because
the Company's ability to continue as a going concern is dependent upon its
ability to raise capital through securities offerings, debt financing and
partnership agreements to fund on-going operations.

    About Insmed Incorporated

    Insmed (NASDAQ:   INSM), is a biopharmaceutical company focused on the
development and commercialization of drug candidates for the treatment of
metabolic diseases and endocrine disorders with unmet medical needs. For more
information, please visit www.insmed.com.

    Statements included within this press release, which are not historical
in nature, may constitute forward-looking statements for purposes of the safe
harbor provided by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements in this press release include, but are not limited
to, statements regarding planned clinical trial design, our regulatory and
business strategies, plans and objectives of management and growth
opportunities for existing or proposed products. Such forward-looking
statements are subject to numerous risks and uncertainties, including risks
that product candidates may fail in the clinic or may not be successfully
marketed or manufactured, the company may lack financial resources to complete
development of product candidates, the FDA may interpret the results of our
studies differently than we have, competing products may be more successful,
demand for new pharmaceutical products may decrease, the biopharmaceutical
industry may experience negative market trends and other risks detailed from
time to time in the company's filings with the Securities and Exchange
Commission. As a result of these and other risks and uncertainties, actual
results may differ materially from those described in this press release. For
further information with respect to factors that could cause actual results to
differ from expectations, reference is made to reports filed by the Company
with the Securities and Exchange Commission under the Securities Exchange Act
of 1934, as amended. The forward-looking statements made in this release are
made only as of the date hereof and Insmed disclaims any intention or
responsibility for updating predictions or financial guidance contained in
this release.




For further information:

For further information: Investor Relations International Haris Tajyar,
818-382-9702 htajyar@irintl.com

Organization Profile

INSMED INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890